DeepMed Research

Epacadostat

Generic Name: Epacadostat

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₃BrFN_₇O_₄S

CAS Number: 1204669-58-8

Unique Ingredient Identifier: 71596A9R13

Background: Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.

Clinical Trials

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Other: Laboratory Biomarker Analysis
Drug: Epacadostat
Other: Pharmacological Study
Drug: Poly ICLC

First Posted Date: 2014-06-18

Last Posted Date: 2023-02-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02166905

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Carcinoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: NK cells
Biological: IL-2
Drug: INCB024360

First Posted Date: 2014-04-21

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 2

Registration Number: NCT02118285

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Early Phase 1

Completed

Conditions: Stage III Ovarian Cancer AJCC v6 and v7
Stage III Primary Peritoneal Cancer AJCC v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Stage IV Ovarian Cancer AJCC v6 and v7
Stage III Fallopian Tube Cancer AJCC v7
Stage IIIA Primary Peritoneal Cancer AJCC v7
Stage IIIC Fallopian Tube Cancer AJCC v7
Stage IIIA Fallopian Tube Cancer AJCC v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Stage IIIA Ovarian Cancer AJCC v6 and v7

Interventions: Drug: Epacadostat
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2014-01-22

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02042430

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Phase 2

Completed

Conditions: Stage IIIC Uveal Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Skin Melanoma
Recurrent Melanoma
Stage IV Uveal Melanoma
Mucosal Melanoma
Recurrent Uveal Melanoma
Stage IIIA Uveal Melanoma

Interventions: Drug: Epacadostat
Biological: MELITAC 12.1 Peptide Vaccine

First Posted Date: 2013-10-11

Last Posted Date: 2018-06-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01961115

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 1 locations

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: INCB024360

First Posted Date: 2013-04-02

Last Posted Date: 2016-01-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT01822691

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Phase 2

Terminated

Conditions: Genitourinary (GU) Tumors
Ovarian Cancer

Interventions: Drug: Epacadostat
Drug: tamoxifen

First Posted Date: 2012-09-14

Last Posted Date: 2019-03-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT01685255

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Epacadostat
Drug: Placebo
Drug: ipilimumab

First Posted Date: 2012-05-24

Last Posted Date: 2019-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 136

Registration Number: NCT01604889

A Dose-escalation Study in Subjects With Advanced Malignancies

Phase 1

Completed

Conditions: Solid Tumors and Hematologic Malignancy

Interventions: Drug: INCB024360

First Posted Date: 2010-09-06

Last Posted Date: 2018-01-17

Lead Sponsor: Incyte Corporation

Target Recruit Count: 52

Registration Number: NCT01195311

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy